Salient concerns in using analgesia for cancer pain among outpatients: A cluster analysis study

Table 2 Baseline illness and pain variables (n = 207)

Variable	Range	n (%)1	Mean (SD)
Cancer stage	I	20 (9.7)
	II	33 (15.9)
	III	37 (17.9)
	IV	64 (30.9)
	Unknown or unsure	53 (25.6)
Time since cancer diagnosis	1-120 mo		36.7 (35.5)
Charlson comorbidity index	0-13		4.3 (2.6)
General health	Excellent	9 (4.3)
	Very good	23 (11.1)
	Good	63 (30.4)
	Fair	77 (37.2)
	Poor	35 (16.9)
Physical health not good (number of days within last 30 d)	0-30		14.7 (10.7)
Mental health not good (number of days within last 30 d)	0-30		9.5 (10.7)
Past history of substance abuse	No	172 (83.1)
	Yes	35 (16.9)
Presence of depression	No	120 (58.0)
	Yes	87 (42.0)
Worst pain (last week)	0-10 (no pain - pain as bad as you can imagine)		6.9 (2.4)
Average pain (last week)	0-10 (no pain - pain as bad as you can imagine)		4.9 (2.1)
Least pain (last week)	0-10 (no pain - pain as bad as you can imagine)		3.4 (2.0)
Pain-related functional interference score	7-70 (does not interfere-completely interferes)		35.2 (15.9)
Pain relief with medications (last week)	1-10 (10%-100%)		7.2 (2.1)
Pain management index	-2	5 (2.4)
	-1	13 (6.3)
	0	92 (44.4)
	1	63 (30.4)
	2	31 (15.0)
	3	3 (1.4)
Number of analgesic side effects (MSEC)	0-8		3.8 (2.4)
Severity of analgesic side effects (MSEC)	8-80 (not severe-extremely severe)		25.2 (15.0)
BQ-II analgesic barriers (total)	0-96		39.8 (20.1)
No. of complementary alternative modalities used	0-8		2.1 (1.7)

¹No missing values unless otherwise indicated. BQ-II: Barriers questionnaire; MSEC: Medication Side-effects Checklist; SD: Standard deviation.